Polyplus, an upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial grade, has expanded the LipidBrick Library with several new proprietary cationic lipids for lipid nanoparticle (LNP) formulation in mRNA therapeutic and vaccine development. Building forward from LipidBrick IM21.7c and off-the shelf in vivo-jetRNA+transfection reagent, these additional cationic lipids broaden the scope of LNP usage to treat various diseases.

According to the company, LNPs have demonstrated high efficiency delivering RNA therapeutics in vivo, but they can be hard to modulate with challenges in the biodistribution profile. The entire LipidBrick Library IP (intellectual property) is based on a novel lipid structure protected by an independent patent owned by Polyplus. The LipidBrick Library is designed to enable a wider biodistribution and decrease accumulation in the liver to overcome traditional challenges in delivery.

“The LipidBrick product line has been designed to provide new options and solutions for developers of mRNA therapeutics to adapt the biodistribution to their therapeutic purposes,” said Claire Guéguen, head of R&D life sciences at Polyplus. “Through validation for LipidBrick IM21.7c, users have reported higher mRNA expression in the lungs and spleen while bypassing the liver, which was the goal. We want to empower users to achieve simpler and more cost-effective processes. Working with the LipidBrick portfolio of modulating lipid nanoparticles (LNPs), we can do that by improving delivery of LNPs in vitro and in vivo and expanding the use of LNPs beyond the liver to screen and adapt the best suited lipid according to therapeutic applications.”